DUBLIN--(BUSINESS WIRE)--The "Global Cancer Diagnostics Market - Segmented by Type of Products, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The global cancer diagnostics market is estimated to grow at a CAGR of 7.5% during the forecast period (2018 - 2023).
Cancer has become one of the major causes of death across the globe, with the prevalence increasing every year. As a result, healthcare professionals are concentrating on the development of diagnostic and treatment solutions, to check the prevalence level of disease. Early detection of disease increases the success rate of treatment.
Ease of cancer diagnosis has increased substantially over the past decade and is expected to increase further in the coming years. Currently, it is possible to diagnose different cancers, such as breast cancer and prostate cancer, with a simple blood test. The most widely accepted blood tests for breast cancer include BRCA1 and BRCA2.
Similarly, conventional imaging technologies have also experienced considerable innovation in the recent past, and breast tomosynthesis is the best example. Breast tomosynthesis is less-painful and way more efficient than conventional mammography. More than 95% of the currently available cancer diagnostics require very minimal intervention and are capable of providing results with very high sensitivity and specificity. Due to this need of minimal intervention, patient compliance has increased in the recent years, which, in turn, has resulted in an increased number of tests, ultimately driving the market growth.
Other factors, such as increasing healthcare expenditure and the emergence of new technologies, like biomarkers and point of care testing, is increasing the growth of the cancer diagnostics market.
Key Developments in the Market
- October 2017: Abbott acquired Alere Inc.
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
- F. Hoffmann-La Roche Ltd
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc.
- GE Healthcare
- Hologic Inc.
- Illumina Inc.
- Philips Healthcare
- Agilent Technologies Inc.
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/zcs7vg/global_cancer?w=4